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Abstract 
Dry-coated microprojections can deliver vaccine to abundant antigen-presenting cells in skin 
and induce efficient immune responses and the dry-coated vaccines are expected to be thermostable 
at elevated temperatures. In this paper, we show that we have dramatically improved our previously 
reported gas-jet drying coating method and greatly increased the delivery efficiency of coating from 
patch to skin to from 6.5% to 32.5%, by both varying the coating parameters and removing the 
patch edge. Combined with our previous dose sparing report of influenza vaccine delivery in mouse 
model, the results show that we now achieve equivalent protective immune responses as 
intramuscular injection (with the needle and syringe), but with only 1/30th of the actual dose. We 
also show that influenza vaccine coated microprojection patches are stable for at least 6 months at 
23 ºC, inducing comparable immunogenicity with freshly coated patches. The dry-coated 
microprojection patches thus have key and unique attributes in ultimately meeting the medical need 
in certain low-resource regions with low vaccine affordability and difficulty in maintaining “cold-
chain” for vaccine storage and transport. 
Keywords: microprojection; vaccine coating; thermostability 
1. INTRODUCTION 
More than 17 million people die every year from infectious diseases – most of these in 
developing countries [1]. Many of the diseases could be prevented by vaccination, but vaccines are 
underutilized in low-resource regions. With all vaccines being sensitive to heat, the ‘cold-chain’ is 
essential for maintaining their quality during transport and storage [2].  This is a huge burden in 
vaccination campaigns. The cold-chain alone can contribute up to 80% of the financial cost of 
vaccination programs in developing countries [3].  
Advances are being made to improve vaccine thermal stability, but they primarily still rely 
on the needle and syringe for delivery [2,4] – which hinders safe and effective vaccination, 
particularly in the developing world.  For example, most vaccines delivered by needle and syringe 
into muscle, where there are relatively few professional antigen presenting cells in comparison with 
skin and lymph nodes. Therefore, high doses of vaccines are usually required, making vaccination 
even less affordable. Also needle-based vaccine delivery in low-resource regions is held back by the 
need for qualified medical practitioners, needle-stick injuries, unsafe injections, and disposal costs. 
For example, WHO estimates that up to one-third of immunization injections are unsafe in four of 
six regions of the world due to needle reuse, use of unsterilized needles, dangerous infections, etc 
[5]. In some regions, needles that deliver medication or vaccines become the vectors for spreading 
the diseases which they are designed to prevent. 
To help address these social/medical problems, one very attractive and promising way is to 
use needle-free skin vaccine delivery. Central to this is: our skin contains an extensive network of 
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resident professional antigen-presenting cells, which have the capacity to capture the delivered 
vaccine, migrate to draining lymph nodes and orchestrate potent systemic immune responses [6-10]. 
Therefore, delivering vaccines to skin is expected to work more effectively than the traditional 
routes by needle and syringe. Using needle-free delivery routes can avoid needle-stick injuries, 
unsafe injections because of needle reuse and also the disposal costs. 
Vaccines can be targeted into the skin by breaching the tough outer layer, called the stratum 
corneum. To meet this delivery challenge, many approaches are being actively investigated such as 
diffusion/permeation delivery, electroporation [11], biolistic microparticle delivery (Gene Gun) [12]. 
Each of these delivery routes has merit, but is also hindered by important disadvantages.  For 
example: the physical barrier of the skin, the stratum corneum, only allows small molecules (<500 
Da) to permeate the skin, but many target immunotherapeutics (e.g. vaccines) have much higher 
molecular weight (e.g. a few tens thousand to millions Da). The permeation/diffusion can be 
improved by adding chemical enhancers [13,14] or formulating in a nanogel form [15]. However, 
with these methods, the diffusion/permeation may take a long time when the molecular size is large 
and the delivery efficiency is usually low. In addition, it is difficult to accurately control the dose. 
The clinical use of electroporation and biolistic microparticle delivery is mainly hindered by the 
high cost of the device. Also, biolistic delivery is hindered by the high sensitivity of the ballistic 
penetration process to obvious and subtle variation in skin properties [16] and high cell death [17]. 
The electroporation process causes pain and discomfort to patients [18-20]. 
Alternatively, microprojection arrays are a vaccine delivery technology with several advantages 
over existing approaches [21-26].  Firstly, microprojection arrays can mechanically pierce the 
stratum corneum and deliver vaccines to the skin where there are large populations of antigen-
presenting cells [21,26]. Secondly, microprojections can deliver a wide range of molecules (e.g. 
protein and DNA vaccines, virus like particles, drugs) without causing pain [23,25]. Thirdly, one of 
the most important hypotheses for the coated microprojections is that the dry-coating formulation 
will greatly enhance the thermostabilization of molecules, compared to when they are in a liquid 
state. However, to our knowledge, no successful study on the long term thermostability of dry-
coated microprojection patches has been reported. 
In this paper, we use a type of microprojection patch with different design from others in this 
field. Our microprojection patch, termed Nanopatch (NP) [27], designed ‘from the ground up’ for 
the purpose of delivering vaccines to skin. The NP contains very small and densely packed 
projections (21,025 projections per cm2) for skin targeted vaccine delivery. We designed this device 
using a probability analysis [27] to target vaccine directly to thousands of the skin’s APCs. We 
expected that our uniquely designed densely packed microprojections can greatly improve the 
vaccine efficacy. The details have been previously described [27]. The contained microprojections 
are clearly distinct from the large and sparsely packed “microneedles” reported in literature (up to 
700 µm in length and less than 321 projections per cm2) [23,24,28]. One of the key challenges for 
vaccine delivery to skin by these microprojections is coating the surface with vaccine – because of 
their extremely high packing density. We set about meeting this need by developing a gas-jet drying 
coating method to coat vaccines on the very small and densely packed microprojections [29]. The 
coating and NP technology has been tested to deliver a herpes virus type 2 DNA vaccine [30,31] 
and a seasonal influenza vaccine (Fluvax® 2008) in mouse model [27]. With the herpes virus type 2 
DNA vaccine delivery, the results showed that microprojections can deliver the DNA vaccine to the 
skin and achieve comparable antibody responses and statistically equal protection rate against an 
HSV-2 virus challenge, when compared with the mice immunized with intramuscular injection 
using needle and syringe, but with less than 1/10th of the delivered antigen [30,31]. In influenza 
vaccine delivery, the results showed that, associated with physically targeting vaccine to thousands 
of antigen presenting cells in the skin, over 100 times less antigen was needed to be delivered to the 
skin to achieve an equivalent response when compared with intramuscular injection by needle and 
syringe. This represents a marked improvement – an order of magnitude greater than reported by 
others – without reliance on an added adjuvant and with only a single vaccination. This confirmed 
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our expectation of designing the densely packed microprojections for vaccine delivery. However, in 
the report, the influenza vaccine delivery efficiency (i.e. delivery dose into skin / full dose of coated 
patch) from patch into skin was only about 6.5%. This made the actual dose sparing only about 6 
times despite the greatly enhanced vaccine efficacy. 
The objectives of this paper are to: (1) significantly increase the coating delivery efficiency 
from microprojections to skin, to reduce the actual dose of vaccine per vaccination; and (2) 
investigate the long term thermostability of influenza vaccine dry-coated microprojection patches. 
Herein, we show that we have greatly increased the delivery efficiency of coating to 32.5%, by both 
altering the vaccine coating parameters and removing the patch edge. Furthermore, we also show 
that influenza vaccine coated NPs are stable for at least 6 months at 23 ºC, inducing comparable 
immunogenicity with freshly coated patches. Overall, we show, by experiment, that the NP has key 
and unique attributes in ultimately meeting the medical need in certain low-resource regions. 
2. EXPERIMENTAL DETAILS  
2.1 Materials     
Methylcellulose (MC, the viscosity of 2 wt% MC in water is 55 mPa·S) and trehalose were 
purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Fluospheres (F8811, 0.2 micron 
yellow-green fluorescent particles) was ordered from Invitrogen. We used the seasonal human 
influenza vaccine, Fluvax2008® (CSL Ltd, Parkville Australia), which contains 15 µg 
hemagglutinin (HA) per 0.5 ml of each of the three viral strains bearing the surface antigens of 
A/Brisbane/10/2007 (H3N2), A/Solomon Islands/3/2006 (H1N1) and B/Florida/4/2006. Methyl 
14C-OVA was purchased from BioScientific Pty Ltd (Kirrawee, NSW, Australia). 
2.2 NP fabrication 
NP was fabricated from silicon using a process of Deep Reactive Ion Etching in Rutherford 
Appleton Laboratory, Oxford, UK [29]. The microprojections are solid silicon, sputter coated with a 
thin layer of gold (~ 100 nm in thickness). The morphology of microprojection patches and the 
associated vaccine coating were characterized by a JEOL scanning electron microscope 6400 or 
6460LA. All samples reported in this paper were tilted at 45˚ for scanning electron microscopy 
(SEM). 
2.3 Penetration study of microprojection patch on skin 
Each patch was applied to the inner earlobe with a velocity of 2 m/s and a force of 0.6 N by a 
custom spring-loaded plunger based applicator device [32]. The mouse ears were freshly cut from 
the live mice and used within 10 minutes. The NP and skin assembly was then slush frozen in liquid 
nitrogen and transferred to a cryo-preservation chamber under vacuum. Then the assembly was 
sectioned with a knife in the vacuum chamber and sputter coated with a thin (approximately 5 
nanometres) layer of gold for avoiding charging effect during imaging. This technique allows the in 
situ penetration of NP on skin to be observed by SEM. The experiment was done using a Cryo-
SEM fitted with a cryo-stage and preparation chamber (Oxford CT-1500 and Philips XL30 SEM, 
Philips, The Netherlands). 
2.4 Coating of vaccines on microprojection array patches 
Coating solution containing methylcellulose and Fluvax® 2008 was prepared. A fast nitrogen 
gas-jet (~ 10 m/s) was used to coat vaccine onto cleaned patches [29]. In this study, we applied the 
gas-jet to the microprojection patch at an incident angle (α) of 20˚ or 70˚. During coating, the 
patches were rotated to ensure uniform coating. 
The morphology of coated patches was observed by SEM. The coating thickness was 
determined by comparing the size change of the microprojections before and after coating in the 
corresponding secondary electron images. 
2.5. Quantitative analysis of delivery efficiency of coating 
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The delivery efficiency of coating was measured by using methyl 14C-OVA as a tracer as 
previously described [32]. The coating solution contained MC, Fluvax 2008, and 1 µCi/ml of 
methyl 14C-OVA. In this experiment, there were six patches in one group. 
2.6 Vaccination of mice   
To test the stability of the vaccine coating, we coated fifty NPs (4×4 mm) with a commercial 
influenza vaccine (Fluvax  2008) using gas-jet incident angle of 70° and stored them at 23 ºC 
(Standard deviation: 0.5 ºC) sealed under dry nitrogen (humidity < 1%). The coating solution 
contained methylcellulose (10 mg/ml), influenza vaccine (54.5 µg/ml of hemagglutinin protein) and 
trehalose (50 mg/ml). By using 14C-OVA as a tracer, we measured that 248±29 ng influenza 
vaccine was delivered to each mouse. The storage temperature was following WHO guidelines [33]. 
Then, at months 0, 1, 2, 3 and 6, ten of the coated patches were used to immunize groups of five 
C57BL/6 mice. The mice were vaccinated once by applying coated patches to the inner lobe of each 
ear and held in place for 10 min for the vaccine to diffuse into the epidermis/dermis. One month 
post immunization, sera were collected and stored at -20 ºC for antibody titer and 
Hemagglutination-Inhibition (HI) activity measurements. All animal experiments were conducted 
according to The University of Queensland animal ethics regulations. 
2.7 Hemagglutination-Inhibition Assay   
Sera from vaccinated mice were treated with receptor destroying enzyme (RDE II, Denka 
Seiken Co. Ltd.) prior to HI analysis to remove nonspecific inhibitors of agglutination.  Samples 
were diluted 1:10 in RDE and held at 37°C overnight. An equal volume of sodium citrate 1.6% (w/v) 
was then added and held at 56°C for 2 hr to neutralize RDE activity. The HI test was performed 
against each of the three purified influenza viruses present in the Fluvax®2008 formulation using 
chicken red blood cells by established methods adapted to microtiter format [34]. The purified 
viruses were supplied by CSL, Australia. 
3. RESULTS 
3.1. Confirmed penetration of microprojections to the epidermal/dermal layers of mouse skin  
 
Fig. 1a shows an SEM image of microprojections which we used in the mouse studies. The 
length and base diameter of microprojections are 110 and 25 µm, respectively. The spacing between 
the centres of adjacent microprojections is 70 µm. There are 3364 densely packed microprojections 
in 4×4 mm area on each patch. Some patches have 0.5 mm edge where there is no microprojection, 
therefore the total area is 5×5 mm. 
Fig. 1 (a) is an SEM image of uncoated microprojections. (b) shows that microprojections 
penetrate skin and leave clear needle tracks (shown by the white dotted lines). The black arrow 
indicates the skin deflection under patch application. The white arrows indicate two 
microprojections that are not fully in skin.  
 50 µm 
a 
Epidermis 
Skin surface 
deflection 
microprojection 
partially inserted in skin 
Dermis 
microprojection 
       track 
b 
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To investigate the skin penetration of microprojections, we applied the microprojections to the 
skin and observed the assembly with Cryo-SEM while the microprojections were still in situ. Fig. 
1b shows a representative example of the cross section of a NP in situ resting on mouse ear skin 
after being applied by a spring-based device. The white dashed lines in the figure show that the 
microprojections pierce skin and leave clear needle tracks in the epidermal and dermal layers (the 
two microprojections were removed during section process). In a separate study, an analysis of the 
penetration at 130 projection sites showed that the average penetration depth of the 
microprojections was 42.1±9.9 µm in mouse skin with the same application method [31,35]. The 
black dashed line indicates the skin surface deflection under patch application. The degree of skin 
deflection can be affected by many factors – such as microprojection tip sharpness, spacing between 
microprojections, microprojection length and patch application speed [36]. At the conditions 
described in this paper, the skin deflection is generally about 20-40 µm, defined by the height 
difference between the top of skin among microprojections and the edge of the skin puncture hole 
(from the top to the bottom of the black dashed line). The white arrows indicate two 
microprojections that are not fully penetrated into the skin. 
3.2. Localized coating of vaccine primarily to projection tips 
Fig. 2a is an SEM image of uncoated microprojections. The microprojections are composed of 
2 parts with different shapes, which in this paper we refer to as the “conical part” (indicated by a 
black bracket in Fig. 2a) and “cylindrical part” (indicated by a white bracket), respectively. Fig. 2b 
shows the corresponding back-scattered electron (BSE) image of the uncoated microprojection 
patches shown in Fig. 2a. As these patches are coated with a thin layer of gold and gold has a high 
atomic number, they produce bright signal and can be clearly observed on a BSE image. After these 
patches are coated with organic materials (e.g. DNA, proteins) containing light elements, it is 
expected that uncoated surface yields less signal on a BSE image. Therefore, BSE images will be 
used to qualitatively confirm the coating on patches in this study. 
We firstly coated patches using the gas-jet incident angle of 20º, which is consistent with that 
used in previous study [27]. Fig. 2c and 2d show the secondary and backscattered electron images, 
respectively, of the coated microprojections. Under this coating condition, the whole 
microprojections were coated and the coating on the surface of the microprojections was very thin 
(< 50 nm), which is about the resolution of our coating thickness measurement method. On the BSE 
image, the whole microprojections still produce a bright electron signal, which also qualitatively 
suggests a thin coating, because the BSE signal from the microprojection surface under the coating 
layer can still be detected. It took about 3 minutes to coat each individual patch using this condition. 
Having confirmed that the microprojections can penetrate skin and the average penetration 
depth is 42.1±9.9 µm, to increase the delivery efficiency of coated vaccines from the 
microprojections to skin after penetration, we then set about achieving the coating primarily on the 
projection tips, compared with the coating on the whole microprojections. We did this by increasing 
the gas-jet incident angle to 70° and the result is shown in Fig. 2e (secondary electron image) and 2f 
(backscattered electron image). The SEM results show that the coating became much thicker on the 
conical part of the microprojections, while it was still thin on the cylindrical part of the 
microprojections and the base of the patch – in comparison with the coating shown in Fig. 2c and 
2d. The coating thickness at the bottom of the conical part was measured to be 0.54±0.05 µm (n=20, 
indicated by the arrow in Fig. 2e). On the BSE image, the conical part of the coated 
microprojections produced dark signal as expected when the coating is thick. The very bright BSE 
signal from both the cylindrical part of the microprojections and the base of the patch qualitatively 
indicates that the coating on this area is still thin. Under this condition, it took about 5 minutes to 
coat each individual patch. Because it took longer to finish the coating using this condition, we 
noted that the solution was resistant to flow on the patches after approximately 4 minutes. At this 
stage, the use of low gas-jet incident angle could avoid possible thick coating localized in some 
areas on the base of the patches. 
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 3.3 Quantitative analysis of resultant delivery efficiency following NP application to skin  
Fig. 2a and 2b are secondary and backscattered electron images of uncoated 
microprojections, respectively. 2c and 2e are secondary electron images of coated 
microprojections. Fig. 2d and 2f are corresponding backscattered electron images of the 
coated microprojections shown in Fig. 2c and 2e, respectively. Fig. 2c-d and 2e-f show the 
microprojections coated at gas-jet incident angle of 20º and 70º, respectively.  
b 
e f 
c d 
a 
 50 µm 
0.54±0.05 
µm thick 
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As shown in Section 3.2, we have manipulated desirable coating morphologies by increasing 
the incident angle of gas-jet. Here we use the improved coating technique to coat NPs and apply 
them to the skin to investigate if the coating improvements translate into increased delivery 
efficiency. In the experiment, we also investigated the possible influence of patch edge on the 
delivery efficiency. Fig. 3 shows the delivery efficiency of coating under different conditions. First, 
the benchmark control from previous work [27]: when the patch is 5×5 mm in size (i.e. having 0.5 
mm edge around the microprojections, Fig. S1), the delivery efficiency of coating from the patch to 
skin was only 7.3±1.1%. This delivery efficiency value is not statistically different to our previous 
work (6.5±0.8% measured by different assay, p=0.55). Second, when we remove the patch edge, the 
delivery efficiency was increased to 17.8±1.5% even though the coating and patch application 
conditions remained unchanged from the control group (5×5 mm). Third, using the 4×4 mm patch 
(Fig. S1), when we increased gas-jet incident angle from 20º to 70º, the delivery efficiency was 
dramatically further increased to 32.5±3.9%.  
 
3.4 Influenza vaccine dry-coated NPs are thermostable at 23 ºC for at least six months 
Fig. 4 shows the HI titers induced by influenza vaccine delivered by dry-coated NPs (4×4 mm, 
coating with gas-jet incident angle of 70°) after different storage times (up to six months) at 23 ºC. 
Unimmunized mice were used as the negative control, and the HI titers for all three strains were 
below detection. For the immunized mice, for all three strains, the HI titers induced by coated NPs 
after different storage time are comparable with those induced by freshly coated patches (p > 0.05 
for the HI titers comparison with those at Month 0 for all three strains).  
3.5 Confirmed penetration of microprojections to the epidermal/dermal layers of pig skin  
Fig. 3 shows the delivery efficiency of coating under different 
conditions. The delivery efficiency was measured by using 14C-
OVA protein as a tracer in the coating. Six patches per group were 
used in the experiment. 
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We have already shown NPs effectively induce protective immune responses, by delivering dry-
coated vaccine to mouse ear skin in previous reported work [27]. However, the mouse ear skin is 
much thinner than human skin – our ultimate vaccination goal. To show that the densely packed 
microprojection arrays can also deliver coating to a much thicker skin model, we investigated the 
penetration of the microprojections in pig skin and the result is shown in supplementary Fig. S2. 
The microprojections are 200 µm long and spaced at 70 µm between projection tips. Fig. S2 clearly 
indicates that the coating has been delivered to the epidermal and upper dermal layers of the pig 
skin. The resultant penetration depth of the microprojections in the pig skin is 101.4±20.5 
(Mean±SD) µm. 
 
4. DISCUSSION 
4.1 Confirmed penetration of the densely packed microprojection arrays in both mouse and pig skin 
In this paper, we have studied the in situ penetration of microprojections in both the mouse 
and pig skin. First, in the mouse, we confirmed that the microprojections successfully pierced the 
stratum corneum and penetrated to the epidermal and dermal layers in mouse skin. However, the 
penetration of the full length of the microprojections in skin is not achieved, due to the skin 
deflection and the elastic nature of skin. This is the first time that the cross-sectioned in situ 
investigation of the penetration of microprojections in skin is reported. Our findings are consistent 
with the previous results obtained by using fluorescent dyes tracking the penetration of 
microprojections [27,31,32]. For enhanced delivery efficiency of coating, we can either localize the 
Fig. 4 Immune responses induced by influenza vaccine delivered by dry-coated NPs 
(n=5, the error bars are standard errors of the mean). To test the stability of the 
vaccine coating, we coated fifty patches with a commercial influenza vaccine 
(Fluvax 2008) and stored them at 23 ºC sealed under nitrogen. Then, at months 0, 
1, 2, 3 and 6, ten of the coated patches were taken immunizing groups of five 
C57BL/6 mice. The mice were vaccinated once by applying patches dry coated with 
Fluvax 2008® (CSL Ltd Melbourne Australia) to the inner lobe of each ear and held 
in place for 10 min for the vaccine to diffuse into the epidermis/dermis. One month 
post immunization, sera were collected and stored at -20 ºC for HI activity 
measurements. Unimmunised mice were used as negative control. 
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majority coating on the distal part of the microprojections, or increase the penetration depth of the 
microprojections (or both). 
Our previously-reported results have shown that the densely packed microprojections can 
directly target the vaccine to thousands of skin’s APCs [27]. Associated with this targeted delivery, 
over 100 times does sparing – compared to the needle – with comparably-protective responses, was 
achieved in mouse model when delivering influenza vaccine. Looking ahead, the challenge is to 
successfully translate these attributes to vaccination in humans.  In human skin, the density of the 
characterized APCs is actually comparable with that in mouse skin (e.g. Langerhans cell density is 
1052±109 mm-2 in mouse skin [37], and 730±60 mm-2 in human upper arm skin [38]). If the 
densely packed microprojections can also deliver vaccine to a large population of APCs in human 
skin, we expect that the vaccine efficacy can be dramatically enhanced. However, the human skin is 
much thicker than mouse skin (e.g. mouse ear epidermis is 17.5±2.1 µm [37]; the human forearm 
dorsal epidermis is 61.3±11.0 µm [39]), so it is necessary to test if the densely packed 
microprojections can penetrate human skin. In order to test this, we tested the NP penetration into 
pig skin, because pig is considered as a good model for human skin penetration studies, because pig 
skin is physiologically similar to human skin both in skin thicknesses and mechanical properties 
[40]. So, to deliver vaccine to the pig skin, we increased the microprojection length from 110 µm to 
200 µm while keeping the momentum of application constant. The results (Fig. S2 and average 
penetration depth measurement) clearly show that the coating was delivered to the upper dermal 
layer of the pig skin. Therefore, with proper design of the NP and application device, considering 
the mechanical properties of the skin, these densely packed microprojections have the potential for 
human vaccination.  
4.2 Improved gas-jet drying coating and removed patch edge result in enhanced delivery efficiency 
of coating 
First, by only removing the patch edge, we increased the delivery efficiency from 7.3±1.1% to 
17.8±1.5% – while holding all the coating conditions constant. This increase in delivery efficiency 
is caused by removing the effect of the patch edge inhibiting penetration.  Therefore, by trimming 
these edges, the projections penetrate further into the skin. 
Then, in the gas-jet drying coating process, we found that by increasing the gas-jet incident 
angle from 20º to 70º, the coating is more localized to the distal part of the microprojections (Fig. 
2c-2e) and the delivery efficiency correspondingly increased from 17.8±1.5% to 32.5±3.9% even 
though the coating and patch application conditions are all the same (4×4 mm patch; gas-jet 
incident angle of 70° for coating) (Fig. 3). To help provide insights into the mechanism of this 
improvement, we illustrate the coating process at different gas-jet incident angles in Fig. S3. We 
assert that the dry-coating attachment to the projections mainly occurs then the coating is separated 
outside of the coating pool – within the pool, the film on the projections is very thick and more 
challenging to dry. During the coating process, when we blow the coating solution on one corner of 
the patch, some of the microprojections will be out of the coating solution pool, as indicated in Fig. 
S3c-S3f. The viscosity of the thin layer of coating solution adsorbed on the microprojections (out of 
the coating solution pool) dramatically increases due to fast solvent evaporation under gas-jet, 
which results in materials being dried onto the microprojections (illustrated in Fig. S3 (c) and (d)). 
Then we keep rotating the patch so all of the patch microprojections can be coated (Fig. S3 (e) and 
(f)). Every time when the microprojections are exposed to fast gas-jet, one thin layer of coating will 
be deposited on their surface. When the gas-jet incident angle is very low (e.g. 20º), nearly whole 
microprojections (both conical and cylindrical part) will be out of the coating solution pool, so all of 
these areas are uniformly coated (Fig. S3a). It takes 3 minutes to coat each individual patch.  
If we increase the gas-jet incident angle increased from 20º to 70º and blow the coating 
solution on one corner of the patch, only the distal part of the microprojections will be out of the 
coating solution pool. Therefore, the coating will be localized on the distal part of the 
microprojections. Because the surface area of the distal part (conical part) of the microprojections is 
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much less that of the rest of the microprojections (the surface area of the distal part is only 13% of 
the total surface area of the microprojections), it takes a longer time (5 minutes) for all of the 
vaccine to be fully coated. During the extended period of process, more layers of coating are 
deposited on the distal part of the microprojections, ending up with a relatively thick coating. 
The idea – and reduction to practice – of varying the gas-jet incident angle for enhanced 
vaccine coating on very small and densely packed microprojections is novel. In doing so, we 
provide a very simple and robust coating method, not only to NPs, but also to the general 
microneedle vaccine delivery field. Furthermore, our method does not involve repeatable coating of 
microprojections in the same solution pool, removing the risk of the concentration of different 
excipients in the solution varying during coating process.   
4.3 Thermostability of influenza vaccine coated Nanopatches  
The NP is conceptually applicable to a range of vaccines. Here, as a test case, we use a 
commercial trivalent influenza vaccine (Fluvax® 2008), and show that vaccine dry-coated NPs are 
stable – inducing comparable immune response – for at least 6 months at 23 ºC. This is important, 
because it shows that our dry-coating technique can potentially remove the expensive and 
infrastructure-dependent cold-chain needed for all vaccination campaigns in some temperate 
regions. In comparison, the estimated shelf life (defined as haemagglutinin content above 2/3 of the 
original) of trivalent influenza vaccine in liquid form is only 14-20 weeks at 25 ºC [41]. 
 We believe an influenza vaccine is an appropriate test case for the general vaccination field. 
First, influenza is a major cause of morbidity and mortality, affecting about 20% of the world 
population at all ages [41]. Second, compared to all current human vaccines, trivalent influenza 
vaccine has a mid-range stability – therefore it is a good representative of the vaccine stability in 
general [42]. Third, the immune readout (HI activity) is a widely accepted ‘gold standard’ used as 
the surrogate for influenza protective effectiveness in clinical trials [43,44].  Therefore, our 
thermostabilization work has a direct applicability to clinical medicine. 
The improved thermostability of dry-coated influenza vaccine may be due to the addition of 
stabilizer (trehalose preventing dehydration and conserving the structure of hemagglutinin protein) 
[45] and the nitrogen atmosphere (preventing oxidation) in the storage condition. However, for a 
better understanding of the thermostability of our vaccine coated NPs, it is essential for us to 
conduct further studies at different environment conditions (e.g. temperature, humidity) for different 
vaccines. Nevertheless, our data clearly reveal that vaccine coated NPs can be stable for a long 
period of time without refrigeration.  
4.4 Large dose sparing 
As described (sections 3.2, 3.3 and 4.2), we advance our vaccine coating method, so that the 
vaccine is more localized to the distal part of the thousands of microprojections on the NP – which 
penetrate into the skin.  In doing so, we demonstrate that 32.5% of the vaccine coated to the device 
is delivered into the skin.  This is a significant advance over our initial pilot study [27], which only 
delivered ~6.5% of the vaccine on the patch.  In addition, the result is important, because it shows 
that we now achieve equivalent protective immune responses as intramuscular injection (with the 
needle and syringe), but with only 1/30th of the actual dose. It is worth noting that “the 1/30th of the 
actual dose per vaccination” is different from the previously reported “1/100th of the skin delivered 
dose needed for one vaccination”. In the previous report, the actual dose sparing was only around 6 
times because of the low delivery efficiency (~6.5%). The 30 times dose sparing is a step change 
improvement to the field of vaccines: to our knowledge, the highest level of dose sparing achieved 
with a conventional influenza vaccine using any delivery approach (without relying on an adjuvant) 
a factor of 10 [46-48]. In the field of influenza vaccine delivery by dry-coated microprojections, the 
highest dose sparing achieved by others is only 3 times [48]. 
4.5 Potential utility of NP in low-resource regions 
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The rollout of vaccines fully to low-resource regions is hindered by many factors including: 
vaccine affordability; the lack of continuous network of stable, refrigerated storage facilities – i.e. 
interrupted cold chain; unsafe injections due to needle reuse or use of unsterilized needles; the lack 
of trained medical practitioners [49-52]. To help address these key constraints affecting so many 
people in low-resource regions, there is an urgent need for a new vaccine delivery device that is 
long-term thermostable, efficient, needle-free, simple and affordable. 
In this paper, we have introduced NP technology which has the potential to alleviate many of 
these key problems. First, as one test case, influenza vaccine dry-coated NPs are stable for at least 6 
months at 23 ºC, so there is a potential to remove the huge burden of cold chain in vaccination 
campaign in temperate and subtropical regions [33]. Second, associated with targeted delivery of 
influenza vaccines to thousands of skin’s APCs, the NP achieves unprecedented dose sparing (30 
fold). If successfully translated to humans, this dose-sparing will significantly reduce the cost of 
vaccination – particularly with the more expensive vaccines (e.g. Gardasil; HPV vaccine by Merck). 
Third, the NPs cannot be re-used in the field, as coating a vaccine is a specialised factory plant 
activity. 
Fourth, we have shown that the NPs can penetrate to the upper dermal layer of the skin only 
after a significant velocity of application – mitigating the risk of accidental needle-stick injuries that 
can result in dangerous infections. Fifth, the combined benefits of a compact size (similar to a 
postage stamp) and no “sharps” are expected to reduce the post-vaccination safe disposal burden. 
And finally, the operation of NPs for vaccination is expected to be simple, without the need 
for specialist training. We achieve this with a simple and economic design NP applicator. 
Collectively, all of these discussed attributes are important and uniquely position the NP for 
improving the reach of vaccines to resource-poor regions. 
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Fig. 1 (a) is an SEM image of uncoated microprojections. (b) shows that microprojections penetrate 
skin and leave clear needle tracks (shown by the white dotted lines). The black arrow indicates the 
skin deflection under patch application. The white arrows indicate two microprojections that are not 
fully in skin.  
 
Fig. 2a and 2b are secondary and backscattered electron images of uncoated microprojections, 
respectively. 2c and 2e are secondary electron images of coated microprojections. Fig. 2d and 2f are 
corresponding backscattered electron images of the coated microprojections shown in Fig. 2c and 
2e, respectively. Fig. 2c-d and 2e-f show the microprojections coated at gas-jet incident angle of 20º 
and 70º, respectively.  
 
Fig. 3 shows the delivery efficiency of coating under different conditions. The delivery efficiency 
was measured by using 14C-OVA protein as a tracer in the coating. Six patches per group were used 
in the experiment. 
 
Fig. 4 Immune responses induced by influenza vaccine delivered by dry-coated NPs (n=5, the error 
bars are standard errors of the mean). To test the stability of the vaccine coating, we coated fifty 
patches with a commercial influenza vaccine (Fluvax 2008) and stored them at 23 ºC sealed under 
nitrogen. Then, at months 0, 1, 2, 3 and 6, ten of the coated patches were taken immunizing groups 
of five C57BL/6 mice. The mice were vaccinated once by applying patches dry coated with Fluvax 
2008® (CSL Ltd Melbourne Australia) to the inner lobe of each ear and held in place for 10 min for 
the vaccine to diffuse into the epidermis/dermis. One month post immunization, sera were collected 
and stored at -20 ºC for HI activity measurements. Unimmunised mice were used as negative 
control. 
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Fig. 3 
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Fig. 4 
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Influenza vaccine coated microprojection patches are stable for at least 6 months at 23 ºC, inducing 
comparable immunogenicity with freshly coated patches. 
 
